Analysis of the care situation with regard to the specific immunotherapy in cases of allergic respiratory diseases.

• Conditions: J30.2; J45.8; Predominantly allergic asthma; Mixed asthma; J30.1; J30.3; J30.4; Allergic rhinitis due to pollen; Other seasonal allergic rhinitis; J45.0

• Registration Number: DRKS00017316
• Lead Sponsor: ehrstuhl für Medizinmanagement, Universität Duisburg-Essen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-21
• Study Completion: 2020-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 2505

Inclusion Criteria

Inclusion criteria for insurred with allergic rhinitis:
in the index period (01.07.2017-30.06.2018)
at least 5 years old,
at least one secure outpatient diagnosis (J30.1; J30.2; J30.3 or J30.4) in at least one quarter,
insured by the DAK Gesundheit in the index period and the previous four years.

Inclusion criteria for insured with allergic asthma:
in the index period (01.07.2017-30.06.2018),
at least 5 years old,
at least secure outpatient diagnosis in at least two quarter or an inpatient diagnosis in at least one quarter,
at least one of the below listed drugs prescribed,
insurred by the DAK Gesundheit in the index period and the previous four years.

ATC-Code asthma medication: R03AA, R03AC, R03AK, R03BA, R03BB, R03BC, R03CB, R03CC, R03DA, R03DC, R03DH, R03DX

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
by questionnaire and routine data: existing of a deficent care situation regarding AIT

Secondary Outcome Measures

Name	Time	Method
by questionnaire and routine data: patient characteristics which correlates with a deficient care situation regarding AIT; health related quality of life; cost of illness